GFP/Luc Reporter Cell Line - OCI-AML-3

OCI-AML-3 is a cell line commonly used to study acute myeloid leukemia (AML), a cancer that originates from myeloid blood cells. The cell line was derived from a patient diagnosed with AML and has become an important tool for studying the biology and treatment of this malignant disease. OCI-AML-3 cells are characterized by certain genetic mutations that are frequently observed in AML patients. Notably, these cells carry mutations in the NPM1 and DNMT3A genes, both of which play important roles in the pathogenesis of AML. The presence of these mutations makes OCI-AML-3 a valuable model for studying the molecular mechanisms underlying AML and testing potential therapeutic strategies.

The luciferase reporter cell line OCI-AML-3 is a specialized experimental tool that is widely used in biomedical research, especially in the study of acute myeloid leukemia (AML). The main feature of the luciferase reporter variant is the integration of the luciferase gene, which allows researchers to dynamically and non-invasively monitor gene expression and cell behavior. This bioluminescent marker is particularly advantageous because it facilitates real-time tracking of cellular processes in vitro and in vivo. OCI-AML-3 cells with luciferase expression allow for high-throughput screening and precise monitoring of drug efficacy, making a significant contribution to the advancement of leukemia research.